The thought of an artificial crystal that can be connected to antibodies sounds like something out of a science fiction novel. This is because the material can be enhanced with powerful medications or imaging agents. As a result, it can assist find sick cells with greater precision, resulting in fewer side effects for the patient.
A research team has precisely managed to develop the idea mentioned above. They have brought forth the world's first MOFs (Metal-Organic Frameworks) antibody-drug delivery system, potentially revolutionizing the Novel Drug Delivery Systems Market. This is because it can fast-track potent new therapies for autoimmune, cardiovascular and cancer diseases.
The in vitro study showed that if MOF antibody crystals are attached to their target cancer cells and are exposed to the low pH in the cells, they break down. Hence, delivering the drugs directly and solely to the desired area.
The metal-organic framework essentially consists of a mixture of metal (zinc) and carbonate ions. It further includes a small organic molecule (an imidazole, a colorless solid compound soluble in water). The combination ensures that the payload is attached to the antibody. This benefit can become a new medical tool for treating specific diseases with tailored medications and doses. In addition, it also serves as a reservoir for personalized therapeutics.
Today only 0.01 percent of chemotherapy currently reaches cancer tissue. This ground-breaking new technique can significantly increase the potency of medications that reach their intended target.
Over 80 distinct monoclonal antibodies have been approved for clinical use. This technology has enormous potential to improve these antibodies for the targeted delivery of diagnostic agents and therapeutic medications. The goal is for this technology's clinical translation to enhance the quality of life for patients with serious diseases. The method allows for personalized treatment and, given the precision available, may eventually change the current dosage required for patients. Thus, leading to fewer side effects and lower treatment costs.